Objective: To assess the occurrence of narcolepsy after influenza vaccines used in the United States that contained the influenza A(H1N1)pdm09 virus strain.
Narcolepsy is a chronic disorder of the CNS characterized by excessive daytime sleepiness. 1 Narcolepsy can occur with or without cataplexy, which consists of sudden short episodes of the loss of motor tone triggered by emotions. 1 The incidence of narcolepsy is highest during the teen years and most cases begin before the age of 25, 1,2 but many individuals with narcolepsy are not diagnosed until several years after the onset of symptoms. 3 In August 2010, public health agencies in Sweden and Finland announced that they had received reports of narcolepsy as an adverse event after vaccination with Pandemrix (Glaxo-SmithKline Biologicals [GSK]), an adjuvant-containing influenza A(H1N1)pdm09 monovalent pandemic vaccine. 4, 5 By February 2011, 12 countries had received similar reports, and a preliminary investigation in Finland found an incidence of narcolepsy 9 times higher among people aged 4 to 19 years who had received Pandemrix compared with those who had not. 6 The narcolepsy symptoms began within 6 months after vaccination in 96% of the cases. 7 Pandemrix was used in 47 countries during the 2009 pandemic. A similar GSK vaccine, Arepanrix, was used in additional countries. Neither of these vaccines nor any other adjuvant-containing influenza vaccine was used in the United States (US). A review of the Vaccine Adverse Event Reporting System data did not indicate any association between US licensed influenza vaccines and narcolepsy. 8 To further evaluate the possibility of an association between influenza vaccines used in the US that contained the influenza A(H1N1) pdm09 virus strain and narcolepsy, we conducted an epidemiologic assessment in the Vaccine Safety Datalink (VSD) population.
METHODS The VSD is a collaboration between the Centers for Disease Control and Prevention and several integrated health care organizations (sites) in the US that performs vaccine safety research and surveillance. 9 Eight sites with a combined annual population of more than 8.5 million patients contributed data to this study.
Incidence of narcolepsy diagnosis in the population.
We searched each patient's health care visit history for visits with an ICD-9 narcolepsy diagnosis code (347.00-347.11), regardless of the patient's vaccination history. Visit records were available starting between 1990 and 2005 depending on the site. The visit date associated with the first-ever occurrence of any narcolepsy ICD-9 code in a patient's record was considered the incident diagnosis date. The number of patients with an incident diagnosis was divided by the number of patients enrolled in the VSD population to calculate the incidence rate of diagnosis for the years 2006 through 2011. We compared the diagnosis incidence rate after the start of the influenza pandemic in April 2009 to the period before the start of the pandemic.
Vaccinated cohort. We identified all VSD patients who received an influenza vaccine that contained the influenza A(H1N1)pdm09 virus strain during either the 2009 influenza pandemic or the 2010-2011 influenza season. These included the 2009 monovalent inactivated vaccine (MIV) and monovalent live attenuated influenza vaccine (MLAIV) and the 2010-2011 seasonal influenza trivalent inactivated vaccine (TIV) and live attenuated influenza vaccine (LAIV). Patients had to have received the vaccine before or during enrollment in a VSD site. Among this cohort, we identified all patients with a health care visit code for narcolepsy as described above through the end of year 2011. Chart review was done to confirm the diagnosis of narcolepsy and identify the date of narcolepsy symptom onset. Patients were first classified into 1 of 3 groups based on their status on the date of the diagnosis code: miscode, prevalent case of narcolepsy, or being evaluated for narcolepsy. Miscodes were patients for whom no evidence of a narcolepsy diagnosis or any symptoms suggestive of narcolepsy could be found in the medical record. Prevalent cases were patients who had a preexisting diagnosis of narcolepsy with symptom onset in the remote past, for example, before enrollment in the site, and whose narcolepsy symptom onset could not have occurred after receipt of one of the vaccines being studied. Patients in the third category were those being evaluated for symptoms for which narcolepsy was considered in the differential diagnosis by at least one provider.
Among the patients being evaluated for narcolepsy, we further classified each patient into one of the following diagnosis categories: narcolepsy with cataplexy, narcolepsy without cataplexy, unknown diagnosis, or not a case of narcolepsy. Narcolepsy with cataplexy and narcolepsy without cataplexy were defined according to the International Classification of Sleep Disorders, 2nd edition, diagnostic criteria. 10 Each of these patients had been evaluated by a sleep medicine specialist in the course of routine clinical care; for the purposes of this investigation, one physician reviewed each patient's medical record to determine whether the International Classification of Sleep Disorders, 2nd edition, diagnostic criteria were met. "Unknown diagnosis" was assigned to patients for whom narcolepsy was mentioned in the medical record as a possibility, but the patient either did not pursue definitive evaluation or was lost to follow-up. Patients who were evaluated for symptoms suggestive of narcolepsy but for whom a narcolepsy diagnosis was ruled out and an alternative diagnosis established were classified as "not a case of narcolepsy." Narcolepsy symptom onset was defined as the earliest date of onset of either excessive daytime sleepiness or cataplexy, as reported by the patient and recorded in the medical record. If the symptom onset date occurred during the 180 days after influenza vaccination, the case was considered a postvaccination case of narcolepsy.
We compared the observed number of postvaccination cases with the number of cases expected to occur by chance alone based on the size and age distribution of the vaccinated cohort. The number of incident cases expected to occur was calculated by multiplying the enrolled person-time during the 180 days postvaccination among individuals who received an influenza vaccine by the age-specific incidence rates from a published study that identified chart-confirmed narcolepsy cases in a US population using a similar case definition. 11 To determine how often a health care visit with a first-ever narcolepsy ICD-9 code represented a chart-confirmed diagnosis of narcolepsy among vaccinated patients, we calculated the positive predictive value (PPV), which equals the number of chart-confirmed cases divided by the number of patients whose charts were reviewed.
We restricted our investigation to patients younger than 30 years because the initial reports of an association between narcolepsy and influenza vaccines in Europe involved persons younger than 20 years. This age group also has the highest baseline incidence of narcolepsy. Our vaccinated cohort analysis was done using data from 6 sites where chart review was available.
Standard protocol approvals, registrations, and patient consents. Institutional review boards at each VSD site approved this study and determined that informed consent was not required.
RESULTS
Incidence of narcolepsy diagnosis in the population. We identified 1,045 patients with an incident diagnosis code for narcolepsy. Figure 1 shows the incidence rate of narcolepsy diagnosis codes by quarter year for 3 age groups. The rate after the start of the pandemic is similar to the rate before the pandemic. Table 1 shows incidence rate ratios comparing the rates during each time period after the start of the pandemic with the prepandemic baseline rate. There was no significant change.
Vaccinated cohort. The number of patients vaccinated during the 2009 pandemic was 650,995 of which 96% were still enrolled at 180 days postvaccination, 92% at 365 days postvaccination, and 83% at the end of 2011. There were 870,530 vaccinated during the 2010-2011 season, of which 95% were still enrolled at 180 days postvaccination and 88% at the end of 2011. The MIV manufacturers were Sanofi Pasteur (67%), Novartis (19%), others (2%), and unknown (12%). The 2010-2011 TIV manufacturers were Sanofi Pasteur (43%), Novartis (26%), GSK (15%), others (5%), and unknown (11%).
Seventy patients had a first-ever narcolepsy ICD-9 code after vaccination; chart review was completed for all of them. The patients were classified as follows: miscode (n 5 5), prevalent case of narcolepsy (n 5 19), and being evaluated for narcolepsy (n 5 46). Among the 46 patients being evaluated for narcolepsy, the diagnosis categories were as follows: incident diagnosis of narcolepsy with cataplexy (n 5 6), incident diagnosis of narcolepsy without cataplexy (n 5 10), unknown diagnosis (n 5 3), and not a case of narcolepsy (n 5 27). Table 2 shows characteristics by diagnosis categories, including the relationship between date of vaccination and date of symptom onset for the cases. For some cases, the date of symptom onset was either not documented or not stated precisely enough to determine the relationship to vaccination. None of these patients received a GSK influenza vaccine during the study period.
Among the 16 cases with an incident diagnosis, none clearly had their symptom onset during the 180 days after receipt of an MIV or MLAIV vaccine, compared with 6.52 cases expected (table 3) . Two cases clearly had symptom onset during the 180 days after receipt of 2010-2011 TIV. The first patient was a 17-year-old male who had onset of excessive daytime sleepiness 12 days after vaccination; he did not have cataplexy. The other case occurred in a 13-year-old male with cataplexy whose symptom onset occurred between 120 and 180 days postvaccination. The number of cases expected after TIV was 7.57.
In European reports, the vast majority of narcolepsy case-patient's symptoms began within 6 months (180 days) after vaccination. 7, 12, 13 We also examined the 365 days postvaccination interval: for the 2009 pandemic vaccines, there were 2 cases (12.95 expected) and for the 2010-2011 seasonal vaccines, there were 2 cases (17.24 expected). No cases had symptom onset more than 365 days postvaccination.
Among the 16 chart-confirmed incident cases, the median age was 18 years (range 11-28). The sex distribution was 9 male and 7 female. The time between symptom onset and diagnosis ranged from 4 to 36 months among those aged 19 years or younger, and Population incidence rate of narcolepsy diagnosis (first-ever narcolepsy ICD-9 diagnosis code in a patient's record) for 3 age groups by quarter year, 2006-2011 from 6 months to 17 years among those older than 19 years. One case-patient had a history of influenza-like illness recorded near to, but not clearly before, the time of narcolepsy symptom onset. Figure 2 shows the date of diagnosis and date of symptom onset among the incident cases who received either MIV or MLAIV. The distributions do not suggest a cluster of cases after the 2009 pandemic vaccination program. The PPV of a first-ever narcolepsy ICD-9 code for a chart-confirmed incident diagnosis of narcolepsy was 23% (16/70) and for either an incident or prevalent diagnosis was 50% (35/70). All of the incident diagnoses were associated with visits to sleep medicine or neurology clinics. When the ICD-9 code was associated with a primary care clinic visit, it either represented a prevalent case ( 
DISCUSSION Epidemiologic investigations in several
European countries have found an association between Pandemrix (an adjuvanted influenza A[H1N1]pdm09 vaccine) and narcolepsy. An increased relative risk (RR) of narcolepsy in vaccinated compared with unvaccinated children and adolescents was found in Finland (RR 5 12.7), 7 Sweden (RR 5 2.92), 14 Ireland (RR 5 13.9), 13 and Norway (RR 5 10). 15 An increased risk with vaccination was also found in England (odds ratio 5 14.4) 12 and France (odds ratio 5 6.5). 16 A case-control study that pooled data from 8 European countries found an increased risk in an analysis anchored on the date of narcolepsy symptom onset. 17 We investigated whether a similar association could exist with the pandemic influenza vaccines that were used in the US.
In our vaccinated cohort analysis, we found fewer chart-confirmed cases of narcolepsy with symptom onset in the 6 months after receipt of influenza vaccine than would have been expected by chance alone. We based our expected number of cases on the only chart-confirmed incidence rate estimates published to date, 11 which might not reflect the baseline incidence in our study population. However, even if we assumed that the true baseline incidence was one order of magnitude less, the zero cases observed in our 2009 pandemic vaccinated cohort would still be less than the 0.652 cases expected. In Finland, the incidence of narcolepsy observed among vaccinated people 0 to 19 years old was 9 per 100,000 person-years. 7 If that rate existed in our 2009 pandemic vaccinated cohort, we should have observed 16 cases just among the patients aged 0 to 19 years who received MIV, whereas we actually observed zero cases.
Three of our patients had an "unknown diagnosis" despite chart review. One had sleep-related symptoms that clearly predated the availability of the 2009 pandemic vaccine. The timing of symptom onset for the other 2 cases was not documented, but even Table 2 Characteristics of vaccinated-cohort narcolepsy cases by chart-confirmed diagnosis category Narcolepsy with cataplexy (n 5 6) Narcolepsy without cataplexy (n 5 10) assuming that these 2 patients actually had narcolepsy and that their symptom onset was after vaccination, the observed number of cases would still be less than expected. The patterns observed among the chartconfirmed cases identified in our population were quite different from the patterns observed in Europe. The cases diagnosed among our vaccinated cohort were characterized by a long duration of excessive daytime sleepiness before presentation with the resulting typical lengthy delay between symptom onset and the final diagnosis of narcolepsy. In contrast, the postvaccination cases identified in Europe were characterized by abrupt symptom onset and relatively rapid diagnosis. Only 38% of our incident cases had cataplexy, which is similar to historical rates and also contrasts markedly with the experience in Finland where 94% of postvaccination cases had cataplexy. 18 Some European countries subsequently also reported an increased risk after vaccination in adults up to age 40 years, although the risk was smaller than the risk among those younger than 20 years. 14, 16, 19 We did not observe an increased risk among those aged 20 to 29 years. While we did not investigate persons 30 years or older, it is unlikely that an increased risk would exist in that age range when no increase was observed in the younger age groups.
There are at least 2 reasons why influenza vaccination could have been associated with an increased risk of narcolepsy in some countries but not in the US. First, the influenza A(H1N1)pdm09 vaccines used in the US were different from Pandemrix, the vaccine used in the countries reporting an increased risk. Pandemrix was manufactured by GSK; no GSK pandemic vaccine was used in the US. Pandemrix contained the AS03 adjuvant. 20 An adjuvant enhances the immune system's response to the antigens contained in a vaccine. An adjuvant-containing vaccine could have a different adverse event profile than a nonadjuvanted vaccine containing the same antigens. No adjuvanted influenza vaccines were used in the US. The second factor to consider is the proportion of individuals in a population who are susceptible to developing narcolepsy. Narcolepsy with cataplexy has a strong association with the HLA DQB1*0602 allele, suggesting that it occurs in genetically susceptible individuals. 21 The frequency of this allele varies between populations. 22 A study in the US found the DQB1*0602 allele to be less frequent among Asian/Pacific Islanders and Hispanics than among Caucasians, 23 and the frequency varies between different Caucasian populations as well.
Other HLA alleles might also affect susceptibility. 24 The US has a more heterogeneous population than Northern European countries, therefore the proportion of the US population that is susceptible to developing narcolepsy with cataplexy may be lower than in the countries where an association with vaccine has been observed. Narcolepsy with cataplexy is caused by the loss of hypothalamic neurons that produce the neuropeptide hypocretin. 1 This loss is thought to result from an autoimmune process. Influenza antigen, either from natural infection or vaccine, has been suggested as a possible trigger of the autoimmune response. 25 The role for influenza A(H1N1)pdm09 infection as a potential trigger for narcolepsy has been suggested based on the results of a nonpopulation-based study in a single specialty clinic in Beijing, China, where a 3-fold increase in the number of narcolepsy cases was observed beginning approximately 6 months after the peak of pandemic influenza activity; among those cases, 94% occurred in unvaccinated individuals. 26 However, the epidemiologic evidence from other countries has not been consistent with an increase in narcolepsy after the 2009 pandemic. In South Korea, where a nonadjuvanted influenza vaccine was used for those aged 0 to 18 years, the rate of narcolepsy diagnosis decreased after the start of the pandemic. 27 A European study found a large increase in diagnosis rates among those aged 5 to 19 years in Finland and Sweden (where adjuvanted vaccine coverage was high) but not in 3 other countries where adjuvanted vaccine coverage was low. 28 In our study, the population incidence rate of narcolepsy diagnosis did not show any significant changes after the start of the 2009 influenza pandemic or the pandemic vaccination program, which achieved an approximately 28% vaccination rate in the 5-to 17-year-old age group. 29 Our results do not suggest an association of either influenza A(H1N1)pdm09 vaccination or natural infection with a change in the rates of narcolepsy, although this type of ecologic analysis must be interpreted with caution. First, as described in the literature, the date of narcolepsy diagnosis does not represent the date of narcolepsy symptom onset. 3 Our chart-reviewed analysis showed that the time from symptom onset to diagnosis for individuals with confirmed narcolepsy ranged from 4 months to 17 years. Second, in our study population, many first-ever narcolepsy diagnosis codes do not represent an incident diagnosis of chart-confirmed narcolepsy, particularly in the older age group.
The role that influenza A(H1N1)pdm09 antigens might have had in causing the increase in narcolepsy observed in some countries has not yet been determined. The lack of an increase in incidence in our study and in other countries that did not use the AS03 Figure 2 Number of chart-confirmed incident narcolepsy cases by date of diagnosis and date of symptom onset among patients that received either monovalent inactivated vaccine or monovalent live attenuated influenza vaccine during the 2009 pandemic Includes chart-confirmed incident cases of narcolepsy with cataplexy and narcolepsy without cataplexy diagnosed after receipt of a 2009 pandemic vaccine (n 5 11). The date of symptom onset was before the year 2009 for 5 of the cases and was not documented for one case-the date of symptom onset for these 6 cases is not shown in the graph.
adjuvanted Pandemrix vaccine suggests that other factors are involved. Other factors that have been suggested include the adjuvant or differences between vaccines in the manufacturing process for viral inactivation. 25, 30 Our findings do not suggest an association between influenza A(H1N1)pdm09-containing vaccines used in the US and narcolepsy. Our investigation included both the inactivated and the live attenuated 2009 monovalent pandemic vaccines and the 2010-2011 seasonal influenza vaccines, which also contained the A(H1N1)pdm09 virus strain. Vaccination with the influenza A(H1N1) pdm09 vaccine viral antigens does not appear to be sufficient by itself to increase the incidence of narcolepsy in a population.
